Discrimination Between Fibrin and Fibrinogen by a Monoclonal Antibody Against a Synthetic Peptide

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1985 Oct 1

PMID 2413458

Citations 8

Authors

G Muller-Berghaus

P Fuhge

R Eberle

N HEIMBURGER

Affiliations

Soon will be listed here.

Abstract

Circulating soluble fibrin, observed in the blood of patients with ongoing intravascular coagulation, is generated from the plasma protein fibrinogen by the limited proteolytic action of thrombin. We report the production of a monoclonal antibody that discriminates between fibrin and fibrinogen in blood. The synthetic hexapeptide Gly-Pro-Arg-Val-Val-Glu, representing the amino terminus of the alpha chain of human fibrin, was used as immunogen. This hexapeptide is located within the A alpha chain of fibrinogen but becomes the amino terminus of the fibrin alpha chain, after fibrinopeptide A is removed by the action of thrombin, and thus becomes accessible for antibody binding. The monoclonal antibody we have prepared can discriminate between fibrin and fibrinogen and thus can be used in assay systems to quantitate soluble fibrin or, potentially, to image fibrin-rich thrombi.

Citing Articles

The evolution of fibrin-specific targeting strategies.

Stefanelli V, Barker T J Mater Chem B. 2018; 3(7):1177-1186.

PMID: 29416866 PMC: 5798253. DOI: 10.1039/C4TB01769B.

Ultrasoft microgels displaying emergent platelet-like behaviours.

Brown A, Stabenfeldt S, Ahn B, Hannan R, Dhada K, Herman E Nat Mater. 2014; 13(12):1108-1114.

PMID: 25194701 PMC: 4239187. DOI: 10.1038/nmat4066.

Discovery of an uncovered region in fibrin clots and its clinical significance.

Hisada Y, Yasunaga M, Hanaoka S, Saijou S, Sugino T, Tsuji A Sci Rep. 2013; 3:2604.

PMID: 24008368 PMC: 3764439. DOI: 10.1038/srep02604.

Antibody imaging in the evaluation of cardiovascular diseases.

Khaw B, Narula J J Nucl Cardiol. 1994; 1(5 Pt 1):457-76.

PMID: 9420730 DOI: 10.1007/BF02961600.

New strategies in the determination of fibrin and fibrin(ogen) derivatives by monoclonal antibodies.

Nieuwenhuizen W Blut. 1988; 57(5):285-91.

PMID: 3058234 DOI: 10.1007/BF00320354.

References

Fletcher A, ALKJAERSIG N, OBrien J, Tulevski V . Blood hypercoagulability and thrombosis. Trans Assoc Am Physicians. 1970; 83:159-67. View

Olexa S, Budzynski A . Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci U S A. 1980; 77(3):1374-8. PMC: 348497. DOI: 10.1073/pnas.77.3.1374. View

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

Marder V, Shulman N, Carroll W . High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem. 1969; 244(8):2111-9. View

FERRY J . Polymerization of fibrinogen. Physiol Rev. 1954; 34(4):753-60. DOI: 10.1152/physrev.1954.34.4.753. View

Konig W, Geiger R . [A new method for synthesis of peptides: activation of the carboxyl group with dicyclohexylcarbodiimide using 1-hydroxybenzotriazoles as additives]. Chem Ber. 1970; 103(3):788-98. DOI: 10.1002/cber.19701030319. View

Thomas L, Smith R, VON KORFF R . Cold-precipitation by heparin of a protein in rabbit and human plasma. Proc Soc Exp Biol Med. 1954; 86(4):813-8. DOI: 10.3181/00379727-86-21241. View

Nossel H . Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis. Nature. 1981; 291(5811):165-7. DOI: 10.1038/291165a0. View

Nossel H, Yudelman I, Canfield R, Butler Jr V, Spanondis K, Wilner G . Measurement of fibrinopeptide A in human blood. J Clin Invest. 1974; 54(1):43-53. PMC: 301523. DOI: 10.1172/JCI107749. View

10.

Goding J . Antibody production by hybridomas. J Immunol Methods. 1980; 39(4):285-308. DOI: 10.1016/0022-1759(80)90230-6. View

11.

Kierulf P, GODAL H . Fibrinaemia and multiple thrombi in pancreatic carcinoma. A case studied with quantitative N-terminal analysis. Scand J Haematol. 1972; 9(4):370-6. DOI: 10.1111/j.1600-0609.1972.tb00954.x. View

12.

Blomback B, HESSEL B, Hogg D, Therkildsen L . A two-step fibrinogen--fibrin transition in blood coagulation. Nature. 1978; 275(5680):501-5. DOI: 10.1038/275501a0. View

13.

GODAL H, Abildgaard U . Gelation of soluble fibrin in plasma by ethanol. Scand J Haematol. 1966; 3(5):342-50. DOI: 10.1111/j.1600-0609.1966.tb02378.x. View

14.

Muller-Berghaus G, Roka L, Lasch H . Induction of glomerular microclot formation by fibrin monomer infusion. Thromb Diath Haemorrh. 1973; 29(2):375-83. View

15.

BETTELHEIM F . The clotting of fibrinogen. II. Fractionation of peptide material liberated. Biochim Biophys Acta. 1956; 19(1):121-30. DOI: 10.1016/0006-3002(56)90393-6. View

16.

Kudryk B, Collen D, Woods K, Blomback B . Evidence for localization of polymerization sites in fibrinogen. J Biol Chem. 1974; 249(10):3322-5. View

17.

Lipinski B, Gurewich V, Nowak A, WETMORE R . The effect of heparin and dipyridamole on the deposition of fibrin-like material in rabbits infused with soluble fibrin monomer or fibrinogen. Thromb Res. 1974; 5(3):343-58. DOI: 10.1016/0049-3848(74)90172-8. View

18.

Hui K, Haber E, Matsueda G . Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science. 1983; 222(4628):1129-32. DOI: 10.1126/science.6648524. View

19.

Niewiarowski S, Gurewich V . Laboratory identification of intravascular coagulation. The serial dilution protamine sulfate test for the detection of fibrin monomer and fibrin degradation products. J Lab Clin Med. 1971; 77(4):665-76. View

20.

Matthias F, Reinicke R, Heene D . Affinity chromatography and quantitation of soluble fibrin from plasma. Thromb Res. 1977; 10(3):365-84. DOI: 10.1016/0049-3848(77)90148-7. View